CXL (corneal collagen-cross-linking) is a relatively new ophthalmic treatment that uses UV-light and riboflavin to create biochemical and biomechanical changes that strengthen a compromised or diseased cornea. Initially developped for the traitement of corneal degeneration (keratoconus), recent reports indicate that CXL is also effective in arresting all forms of corneal infections (more frequent than keratoconus). With these findings, Prof. Hafezi and Dr. Olivier Richoz are developing a medical device (C-EyeTip©) to be used for both keratoconus and corneal infection.